NL-OMON20521尚未招募不适用
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1.
TREND0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with CRPS-1 according to Veldman criteria, autonomic alterations like hypo/hyper hydrosis, altered hair/nail growth, unsatisfactory results of standard treatment, ability to give informed consent, age >18.
排除标准
- •CRPS-1 or other condition on contralateral extremity, asthma, cardiac problems, hyperthyroidism, epilepsy, parkinson, kydney dysfunction, severe psychiatric dysfunction, history of digestive tract operation or ulcers, active malignant disease, other chronic pain syndrome, use of anti-cholinergic medication.
研究者
相似试验
已完成
2 期
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1pijn syndroomdystrophypost-traumatic dystrophyreflex sympathetic dystrophyNL-OMON33787Vrije Universiteit Medisch Centrum10
进行中（未招募）
不适用
Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1 - Pyridostigmine trialPatients with CRPS-1.EUCTR2009-010758-36-NLVU University Medical Center10
已完成
1 期
AchE Inhibitor and InsulinDiabetes MellitusNCT03063515University of Miami12
进行中（未招募）
3 期
The use of Pyridostigmine bromide in the treatment of fatigue secondary to COVID-19Post-Viral Fatigue SyndromeCOVID-19C01.925RBR-107j3g4vniversidade Federal Fluminense
终止
早期 1 期
A Pilot Study of Pyridostigmine in Pompe DiseasePompe DiseaseNCT02357225University of Florida2